29.09.2020 • News

Messer Plans Spanish Gases Plant

German family owned industrial gases group Messer has announced plans to invest more than €35 million in a new plant in Vilaseca, Spain, which it said will lay down the foundation for further growth in Western Europe.

Located in the south of the Tarragona chemical complex, the facility will have a capacity of 2,400 t/d oxygen, nitrogen and argon. The air separation plant will also be certified to produce medical gases. Commissioning is scheduled for December 2021.

Messer said the plant will be connected to its pipeline network to meet growing demand from the local chemical industry for oxygen and nitrogen. In addition, the company will also supply manufacturing companies in the Tarragona region with liquefied gases in tankers and gaseous product in cylinders.

Earlier this year, the company was due to start up a third air separation unit in Germany. The company spent about €32 million on the oxygen, nitrogen and argon plant, which is located at the Speyer site of Saint-Gobain Isover, a manufacturer of glass-fiber insulation.

Messer is to invest more than €35 million in a new plant in Vilaseca, Spain,...
Messer is to invest more than €35 million in a new plant in Vilaseca, Spain, which it said will lay down the foundation for further growth in Western Europe. The facility will have a capacity of 2,400 t/d oxygen, nitrogen and argon and commissioning is due in December 2021. (c) Messer Group

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read